Attributes | Values |
---|
rdf:type
| |
description
| - clinical trial (en)
- клінічне випробування (uk)
- կլինիկական փորձարկում (hy)
|
rdfs:label
| - Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors (en)
|
skos:prefLabel
| - Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors (en)
|
name
| - Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors (en)
|
title
| |
title
| - An Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Cohorts to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonistic Monoclonal Antibody) in Combination With Vanucizumab (Anti-Ang2 and Anti-VEGF Bi-Specific Monoclonal Antibody, Part I) or Bevacizumab (Anti-VEGF Monoclonal Antibody, Part II) in Patients With Metastatic Solid Tumors (en)
|
end time
| |
end time
| |
instance of
| |
instance of
| |
start time
| |
start time
| |
country
| |
country
| |
research site
| |
research site
| |
research intervention
| |
research intervention
| |
sponsor
| |
sponsor
| |
number of participants
| |
number of participants
| |
study type
| |
study type
| |
ClinicalTrials.gov ID
| |
ClinicalTrials.gov ID
| |
clinical trial phase
| |
clinical trial phase
| |
is about
of | |
is is the study of
of | |
is is the study of
of | |